Johnson & Johnson Talc Lawsuit

J&J’s Role in the Talcum Powder Crisis

Johnson & Johnson is one of the largest healthcare and consumer products companies in the world, with annual revenue exceeding $90 billion and a market capitalization of approximately $400 billion. For over a century, J&J’s Baby Powder was its most iconic consumer product — a symbol of gentleness, purity, and trust. That image has been shattered by the revelation that J&J knew for decades that its Baby Powder contained asbestos and was linked to ovarian cancer, and chose to conceal this information from consumers, regulators, and the medical community.

The evidence of J&J’s knowledge and concealment is extensive. Internal memos from the 1970s show company scientists detected asbestos in talc samples and executives discussed the implications without taking corrective action. J&J influenced scientific research to minimize concerns about talc safety, lobbied regulators to maintain favorable testing standards, fought aggressively to keep damaging documents sealed in litigation, and continued marketing Baby Powder — including targeted campaigns to African-American women — despite accumulating evidence of cancer risk.

J&J’s corporate conduct has driven the massive punitive damage awards in the litigation. Punitive damages are specifically designed to punish willful and reckless corporate behavior, and juries have responded to the evidence of concealment with extraordinary awards — $1 billion in Craft, $4.14 billion in Ingham (reduced on appeal), and $80 million in Lanzo. These awards reflect jurors’ determination that J&J’s conduct was not mere negligence but a deliberate corporate decision to prioritize revenue over human lives.

The Failed Bankruptcy Strategy

In October 2021, facing tens of billions in potential liability, J&J executed a maneuver known as the "Texas two-step." The company used a Texas divisional merger statute to create a subsidiary called LTL Management LLC, transferred all talc liabilities to LTL, and then filed LTL for Chapter 11 bankruptcy in New Jersey. The strategy was designed to resolve all talc claims through an $8.9 billion bankruptcy trust — far less than J&J’s potential exposure from individual trials.

The Third Circuit Court of Appeals rejected LTL’s bankruptcy petition twice. In January 2023, the court found the filing was not in good faith because LTL was not in genuine financial distress — it was a shell entity backed by J&J’s $400 billion market cap. When LTL filed again, the Third Circuit rejected it again in 2025 on the same grounds. These rulings established important precedent preventing large corporations from using divisional mergers to shield themselves from legitimate tort liability.

The failure of the bankruptcy strategy is a major victory for plaintiffs. It means all pending talcum powder lawsuits proceed through the traditional litigation process, with the possibility of individual jury trials, uncapped verdicts, and full punitive damage exposure. The MDL 2738 bellwether trials in New Jersey are the next critical phase of the litigation against J&J.